Core Viewpoint - CICC maintains a positive outlook on WH Group (00288), projecting net profit attributable to shareholders of $1.614 billion and $1.683 billion for 2025 and 2026 respectively, with a target price of HKD 8.56 per share, indicating approximately 23.9% upside potential from the current stock price [1] Group 1: Financial Performance - In Q1 2025, WH Group's revenue reached $6.554 billion, a year-on-year increase of 6.0%, while operating profit was $598 million, up 19.4% year-on-year, and core net profit attributable to shareholders was $364 million, reflecting a 20.9% increase year-on-year [2] - The profit performance in Q1 2025 slightly exceeded market expectations, primarily due to improved profitability in the U.S. farming business [2] Group 2: Domestic Business - In Q1 2025, the sales volume of meat products in the domestic market decreased by nearly 17.4%, with a profit per ton of approximately RMB 4,700, down 5.2% year-on-year [3] - Slaughtering volume in Q1 2025 increased by 11.8% year-on-year, with average profit per head rising by 11.6%, attributed to an increase in customer base and network coverage, alongside reduced competition [3] - The company's other segments, which include farming, saw a reduction in losses by RMB 140 million year-on-year, mainly due to improved controllable cost indicators in farming [3] Group 3: U.S. Business - In Q1 2025, the operating profit for meat products in the U.S. declined by 7.7%, with sales volume down approximately 3.7%, and profit per ton at $894, a decrease of 4.2% year-on-year, attributed to rising raw material costs and a delay in Easter [4] - The upstream farming business in the U.S. reported a profit of $17 million in Q1 2025, a significant improvement from a loss of $170 million in the same period last year, driven by rising hog prices [4] - Slaughtering profit contribution in Q1 2025 decreased by 27% year-on-year, as the increase in hog prices was less than the rise in live hog prices [4] Group 4: Outlook for 2025 - For domestic operations, the slaughtering business is expected to continue expanding its customer base and increasing slaughter volume, with further improvements in profitability for farming operations anticipated [5] - The meat products segment is projected to see improved sales starting from Q2 2025 as channel adjustments stabilize and inventory levels recover [5] - In the U.S., meat product profitability is expected to remain stable despite rising hog prices, as the company can pass on costs through pricing formulas and efficiency optimizations, with robust demand for meat protein [5]

恒生科技指数日内跌超1%，汽车股走弱，蔚来汽车(09866.HK)跌超4.5%，小鹏汽车(09868.HK)跌4%， 舜宇光学科技(02382.HK)跌超3.6%。 ...

Core Viewpoint - The report from CICC maintains a positive outlook on Guoshengtang (02273), projecting adjusted net profits of 481 million and 602 million CNY for 2025 and 2026 respectively, with a target price of 52.8 HKD, indicating a potential upside of 67.6% from the current stock price [1] Group 1: Business Performance - In Q1 2025, the total number of patient visits reached approximately 1.21 million, reflecting a year-on-year growth of 12.7% compared to 1.074 million visits in the same period of 2024 [1][2] - The growth in offline business is expected to significantly outpace overall growth, driven primarily by internal contributions, while online growth is slightly lower due to strategic adjustments [2] Group 2: Expansion and Innovation - The company exceeded expectations in store expansion in 2024, adding 4 self-built and 17 acquired locations, entering new cities and Singapore, totaling 79 medical institutions across 20 cities in China and Singapore by the end of 2024 [3] - The company plans to maintain a store expansion rate of 15-20 in 2025, entering 2-3 new cities while continuing its long-term overseas development strategy [3] - The integration of AI technology aims to enhance the supply of quality medical resources and improve operational efficiency, with the launch of an AI-powered expert replication system [3] Group 3: Financial Metrics - The company maintained a gross margin of approximately 30.1% in 2024, despite fluctuations in traditional Chinese medicine prices, with a sales expense ratio of 12.2% and a management expense ratio of 6.1%, indicating effective cost control [4] - The adjusted net profit for 2024 was 410 million CNY, representing a year-on-year increase of 39.8%, with an adjusted net profit margin of 13.2% [4] - The company is expected to see further profit margin improvements as existing store performance continues to grow and new stores ramp up [4]

狮腾控股将主导客户接洽与商业化策略制定，BytePlus则将提供技术专长、基础架构及联合市场推广支 持。此次合作将首先聚焦于新加坡、印尼、马来西亚、泰国与越南，并计划进一步拓展至亚太地区。 此次合作标志着双方公司的战略布局，紧扣亚洲市场对企业级AI能力日益增长的需求，并符合与投资 者对可扩展、高影响力科技项目的高度关注。 根据Statista数据显示，亚太地区AI市场规模预计将于2025年达到851.5亿美元， 2025年至2030年复合年 增长率(CAGR)预估为27.76%，至2030年市场总量可望攀升至2,984.0亿美元。 作为该计划的一部分，狮腾控股将把BytePlus的AI技术(包括BytePlus Skylark模型及其他专有模型)整合 至狮腾控股旗舰企业级多模态模型AI平台Geene。此次整合将显著提升Geene，通过在多个垂直领域中 无缝协调多种AI模型，为企业用户提供智能且情境感知的AI特工和解决方案。 BytePlus将提供其AI技术的接入权限，包括ModelArk平台(Skylark模型)、语音智能模型，以及高级数据 分析解决方案，如LAS湖仓一体分析服务。此外，此次合作还包括通过By ...

每经记者 杨建 每经编辑 肖芮冬 ｜2025年5月6日 星期二｜ NO.1 国家加大投入支持长远性数据基础设施建设 据央视新闻报道，5月5日，国家数据局表示，国家将继续加大中央财政资金投入，支持地方、行业建设 一批基础性、公益性、长远性数据基础设施项目，用好超长期特别国债资金，加快构建国家数据基础设 施架构，面向"十五五"，加快制定国家数据基础设施规划。 NO.2 第137届广交会成功举办，现场意向出口成交254.4亿美元 5月5日，第137届中国进出口商品交易会（广交会）线下展在广州圆满落幕。现场意向出口成交持续增 长，达254.4亿美元，增长3%。参展企业普遍反映，质量性能好、创新特点强、品牌知名度高的产品更 受青睐，境外采购商下单积极，进一步增强了企业拓展多元化市场的信心。 NO.3 深交所：修订创业板指数编制方案 NO.6 "五一"假期全国重点零售和餐饮企业销售额同比增长6.3% 据商务部商务大数据监测，假期全国重点零售和餐饮企业销售额同比增长6.3%。以旧换新备受欢迎。 2025年初至5月5日0时，汽车以旧换新补贴申请量突破300万份；消费者购买12大类家电以旧换新产品 5516万台，购买手机等数码 ...

Group 1 - The company, Fosun International, announced the sale of future units in a building project located in Lisbon, Portugal [1] Group 2 - The transaction is part of the company's strategy to optimize its asset portfolio and focus on core business areas [1]

蓝佛安表示，10+3区域经济展现较强韧性、拥有较大增长空间，但也面临复杂严峻的内外部挑战。各 方应坚定落实10+3领导人会议共识，坚持多边主义和自由贸易，加强宏观政策沟通协调，深化域内贸 易投资合作，维护产供链稳定畅通，为区域经济金融稳定和一体化进程做出更大贡献。中方愿与10+3 各方一道，坚持开放包容，团结协作，不断深化区域财金合作，以本区域的稳定性和确定性应对世界的 不稳定和不确定。 第28届东盟与中日韩(10+3)财长和央行行长会议5月4日在意大利米兰举行。会议主要讨论了全球和区域 宏观经济形势、10+3区域财金合作等议题，并发表了联合声明。各方在深化区域内政策协调和加强区 域金融安全网等领域达成一系列共识。财政部部长蓝佛安出席会议并表示，当前世界经济格局深刻调 整，不稳定不确定性因素明显增多。中方愿与10+3各方一道，不断深化区域财金合作。中国人民银行 行长潘功胜出席会议并指出，进一步完善清迈倡议机制、强化本区域金融安全网至关重要。 会议各方就美关税政策对全球和区域宏观经济形势造成的影响、完善清迈倡议多边化(CMIM)机制和 10+3宏观经济研究办公室(AMRO)等议题深入交换了意见。蓝佛安代表中方宣 ...

NO.1 银粉生产商建邦高科首次递表港交所 ｜2025年5月6日星期二｜ 5月2日，建邦高科向港交所主板提交上市申请。该公司主要研究、开发、生产及销售银粉，其银粉产品主要用于光伏银浆（生产光伏电池的关 键原材料）的生产。2024年，建邦高科收入约39.5亿元，同比增长41.99%；毛利1.31亿元，同比增长21.96%；净利润约0.79亿元，同比增长 31.95%。 点评：建邦高科赴港交所主板递表，彰显其拓展资本版图的决心。近年营收、利润双增长，展现良好发展态势。作为光伏银粉领域头部企业， 有望借上市契机，依托行业发展东风，进一步扩大规模、提升竞争力，开拓更广阔市场空间 。 NO.5新三板创新层企业讯众股份再次递表港交所 4月30日，新三板创新层企业讯众股份（BJ832646，股价5.01元）向港交所主板提交上市申请。2024年7月26日，该公司就曾向香港联交所递交 过招股书。讯众股份定位为智能云通信建设与服务商，按2023年收入排名计，讯众股份是中国最大的全栈式云通信服务提供商，市场份额占 2023年中国云通信服务市场总收入的1.8%。 5月2日，伟鸿集团控股（HK03321，股价0.056港元）宣布，截至 ...

Core Viewpoint - 环球新材国际 (06616) reported strong financial performance for the fiscal year 2024, with significant growth in revenue and net profit, although cash flow from operating activities showed a slight decline [2]. Financial Performance - The company achieved total revenue of 1.662 billion yuan, representing a year-on-year increase of 51.15% [2]. - The net profit attributable to shareholders was 242 million yuan, reflecting a year-on-year growth of 33.37% [2]. - The net cash flow from operating activities was 272 million yuan, which decreased by 3.93% compared to the previous year [23]. Earnings and Ratios - Basic earnings per share were 0.19 yuan, and the weighted average return on equity was 7.34%, an increase of 0.79 percentage points from the previous year [2][19]. - As of April 29, the price-to-earnings ratio (TTM) was approximately 18.52 times, the price-to-book ratio (TTM) was about 1.33 times, and the price-to-sales ratio (TTM) was around 2.72 times [2]. Revenue Composition - For 2024, the revenue composition indicated that operations in China contributed 1.3322 billion yuan, while operations in South Korea accounted for 316.6 million yuan [14]. Cash Flow and Financing - The net cash flow from financing activities was 1.502 billion yuan, an increase of 250 million yuan compared to the previous year [23]. - The net cash flow from investment activities was -1.549 billion yuan, compared to -55.07 million yuan in the same period last year [23]. Asset and Liability Changes - As of the end of 2024, cash and cash equivalents increased by 7.41%, while the proportion of cash to total assets decreased by 13.36 percentage points [32]. - Long-term borrowings increased by 1,090.94%, and short-term borrowings rose by 159.15%, indicating a significant increase in leverage [36]. - The current ratio was 2.79, and the quick ratio was 2.59, suggesting a strong liquidity position [39].

中证智能财讯 启明医疗-B（02500）4月29日披露2024年度报告。报告期内，公司实现营业总收入5.09亿元，同比下降30.51%；归母净利润亏损7.14亿元，上 年同期亏损7.04亿元；经营活动产生的现金流量净额为2373.9万元，上年同期为-6.1亿元；据报告显示，启明医疗-B基本每股收益为-1.63元，加权平均净资 产收益率为-27.5%。 以4月29日收盘价计算，启明医疗-B目前市净率（TTM）约0.47倍，市销率（TTM）约2.23倍。 市净率(LF)历史分位(%) 001 900 93d3 80-78 80 70 63-94 60 50 2012 44:22 40 3745 30 20 10 11606 0 2019-12-37 1 1-12-37 J-12-37 2n- 制图数据来自恒生聚源数据库 100 + 93:51- 83:41 % 50 58-54 32.19 0 -23:31 -30.51 -50 -100 -150 -200 2022 2023 2019 2020 2021 2024 -○- 营业总收入同比增长率 -○- 归母净利润同比增长率 制图数据来自恒生聚源数据库 总营收、 ...